Investors focused on the Medical space have likely heard of Geron Corporation (GERN Quick QuoteGERN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GERN and the rest of the Medical group's stocks.

Geron Corporation is one of 1238 individual stocks in the Medical sector. Collectively, these companies sit at #13 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GERN is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for GERN's full-year earnings has moved 125% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Based on the latest available data, GERN has gained about 126.67% so far this year. In comparison, Medical companies have returned an average of -2.82%. As we can see, Geron Corporation is performing better than its sector in the calendar year.

To break things down more, GERN belongs to the Medical - Biomedical and Genetics industry, a group that includes 434 individual companies and currently sits at #114 in the Zacks Industry Rank. This group has lost an average of 7.29% so far this year, so GERN is performing better in this area.

Investors in the Medical sector will want to keep a close eye on GERN as it attempts to continue its solid performance.